Does the number of free nicotine patches given to smokers calling a quitline influence quit rates: results from a quasi-experimental study

K Michael Cummings, Brian V Fix, Paula Celestino, Andrew Hyland, Martin Mahoney, Deborah J Ossip, Ursula Bauer, K Michael Cummings, Brian V Fix, Paula Celestino, Andrew Hyland, Martin Mahoney, Deborah J Ossip, Ursula Bauer

Abstract

Background: The offer of free nicotine replacement therapy (NRT) can be a cost-effective marketing strategy to induce smokers to call a telephone quitline for quitting assistance. However, the most cost-effective supply of free NRT to provide to smokers who call a quitline remains unknown. This study tests the hypothesis that smokers who call a telephone quitline and are given more free nicotine patches would report higher quit rates upon follow-up 12 months later.

Methods: A quasi-experimental design was used to assess nicotine patch usage patterns and quit rates among five groups of smokers who called the New York State Smokers' Quitline (NYSSQL) between April 2003 and May 2006 and were mailed 2-, 4-, 6- or 8-week supplies of free nicotine patches. The study population included 2,442 adult (aged 18 years or older) current daily smokers of 10 or more cigarettes per day, who were willing to make a quit attempt, and reported no contraindications for using the nicotine patch. Outcome variables assessed included the percentage of smokers who reported that they had not smoked for at least 7-days at the time of a 12 months telephone follow-up survey, sustained quitting, delayed quitting and nicotine patch use.

Results: Quit rates measured at 12 months were higher for smokers in the groups who received either 2, 6, or 8 weeks of free patches. The lowest quit rate was observed among the group of Medicaid/uninsured smokers who were eligible to receive up to six weeks of free patches. The quit rate for the 4-week supply group did not differ significantly from the 6-week or 8-week groups. These patterns remained similar in an intent-to-treat analysis of 12-month quit rates and in an analysis of sustained quitting.

Conclusion: No clear cut dose response relationship was observed between the number of free nicotine patches sent to smokers and smoking outcomes. Baseline differences in the characteristics of the groups compared could account for the null findings, and a more definitive randomized trial is warranted.

References

    1. Miller N, Frieden TR, Liu SY, Matte TD, Mostashari F, Deitcher D, Cummings KM, Chang C, Bauer U, Bassett MT. Effectiveness of a large-scale free nicotine patch distribution program. Lancet. 2005;365:1849–1854. doi: 10.1016/S0140-6736(05)66615-9.
    1. Cummings KM, Fix B, Celestino P, Carlin-Menter S, O'Connor R, Hyland A. Reach, efficacy, and cost-effectiveness of free nicotine medication give away programs. Journal of Public Health Management and Practice. 2006;12(1):37–43.
    1. An LA, Schillo BA, Kavanaugh AM, Lachter RB, Luxenberg MG, Wendling AH, Joseph AM. Increased reach and effectiveness of a statewide tobacco QuitLine after the addition of access to free nicotine replacement therapy. Tobacco Control. 2006;15:286–293. doi: 10.1136/tc.2005.014555.
    1. Cummings KM, Hyland A, Fix B, Bauer U, Celestino P, Carlin-Menter S, Miller N, Frieden TR. Free Nicotine Patch Giveaway Program 12-Month Follow-up of Participants. American Journal of Preventive Medicine. 2006;31:181–184. doi: 10.1016/j.amepre.2006.03.027.
    1. Hunt WA, Barnett LW, Branch LG. Relapse rates in addiction programs. Journal of Clinical Psychology. 1971;27(4):455–456. doi: 10.1002/1097-4679(197110)27:4<455::AID-JCLP2270270412>;2-R.
    1. Cummings KM, Jaen C, Giovino G. Circumstances surrounding relapse in a group of recent ex-smokers. Preventive Medicine. 1985;14:195–202. doi: 10.1016/0091-7435(85)90035-0.
    1. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2002;4:CD000146.
    1. Cokkinides VE, Ward E, Jemal A, Thun MJ. Under-use of smoking-cessation treatments: Results from the National Health Interview Survey, 2000. American Journal of Preventive Medicine. 2005;28:119–122. doi: 10.1016/j.amepre.2004.09.007.
    1. Shiffman S, Khayrallah M, Nowak R. Efficacy of the nicotine patch for relief of craving and withdrawal 7-10 weeks after cessation. Nicotine and Tobacco Research. 2000;2:371–378. doi: 10.1080/713688158.
    1. Stapleton JA, Russell MAH, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, Wiseman D. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction. 1995;90:31–42. doi: 10.1111/j.1360-0443.1995.tb01007.x.
    1. Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saraccis R, Gulsvik A, Rijcken B, Sawe U. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. European Respiratory Journal. 1999;13:238–245. doi: 10.1034/j.1399-3003.1999.13b04.x.
    1. Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. Addiction. 2007;102:809–814. doi: 10.1111/j.1360-0443.2007.01791.x.
    1. Cummings KM, Giovino G, Jaen CR, Emrich LJ. Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addictive Behaviors. 1985;10:373–381. doi: 10.1016/0306-4603(85)90034-6.
    1. Shiffman S, Patten C, Gwaltney C, Paty J, Gnys M, Kassel J, Hickcox M, Waters A, Malabanis M. Natural history of nicotine withdrawal. Addiction. 2006;101:1822–1832. doi: 10.1111/j.1360-0443.2006.01635.x.
    1. Fiore MC, Jorenby DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch: clinical guidelines for effective use. Journal of the American Medical Association. 1992;268:2687–2694. doi: 10.1001/jama.268.19.2687.
    1. Cummings KM, Hyland A. Impact of Nicotine Replacement Therapy on Smoking. Annual Review of Public Health. 2005;26:583–599. doi: 10.1146/annurev.publhealth.26.021304.144501.
    1. Cummings KM, Mahoney M. Current and emerging treatment approaches for tobacco dependence. Current Oncology Reports. 2006;8:475–483. doi: 10.1007/s11912-006-0077-6.
    1. Shaffer JP. Multiple Hypothesis Testing. Annual Review of Psychology. 1995;46:561–584. doi: 10.1146/annurev.ps.46.020195.003021.
    1. Kozlowski LT, Giovino GA, Edwards B, DiFranza J, Foulds J, Hurt R, Niaura R, Sachs DPL, Selby P, Dollar K, Bowen D, Cummings KM, Counts M, Fox B, Sweanor D, Ahern F. Advice on using over-the-counter nicotine replacement therapy - patch, gum, or lozenge to quit smoking. Addictive Behaviors. 2007;32(10):2140–2150. doi: 10.1016/j.addbeh.2007.01.030.
    1. El-Bastawissi A, McAfee T, Zbikowski SM, Hollis J, Stark M, Wassum K, Clark N, Barwinski R, Broughton E. The uninsured and Medicaid Oregon tobacco user experience in a real world, phone cessation programme. Tobacco Control. 2003;12:45–51. doi: 10.1136/tc.12.1.45.
    1. Murphy JM, Mahoney MC, Hyland AJ, Higbee C, Cummings KM. Disparity in the Use of Smoking Cessation Pharmacotherapy among Medicaid and General Population Smokers. Journal of Public Health Management and Practice. 2004;11:341–345.
    1. McAffee TA, Bush T, Deprey TM, Mahoney LD, Zbikowski SM, Fellows JL, McClure JB. Nicotine patches and uninsured quitline callers. A randomized trial of two versus eight weeks. American Journal of Preventive Medicine. 2008;35(2):103–110. doi: 10.1016/j.amepre.2008.04.017.
    1. Bansal M, Cummings KM, Hyland A, Giovino G. Stop Smoking Medications: Who uses them, who misuses them, and who is misinformed about them? Nicotine & Tobacco Research. 2004;6(Supplement 3):S303–S310.
    1. Seller EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology & Therapeutics. 2000;68:35–43.
    1. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics. 2004;14:83–90. doi: 10.1097/00008571-200402000-00002.
    1. Lerman C, Tyndale RF, Patterson F, Wileyto EP, Pinto N, Benowitz N. Nicotine Metabolite Ratio Predicts the Efficacy of Transdermal Nicotine in a Smoking Cessation Randomized Clinical Trial. Clinical Pharmacology & Therapeutics. 2006;79:600–608.
    1. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High- dose nicotine patch therapy. Percentage of replacement and smoking cessation. Journal of the American Medical Association. 1995;274:135–138. doi: 10.1001/jama.274.17.1353.
    1. Shiffman S, Fant RV, Gitchell JG. Nicotine delivery systems: How far has technology come? American Journal of Drug Delivery. 2003;1:112–124. doi: 10.2165/00137696-200301020-00003.
    1. Boyle RG, Solberg LI, Asche SF, Maciosek MV, Boucher JL, Pronk NP. Proactive recruitment of health plan smokers into telephone counseling. Nicotine & Tobacco Research. 2007;9:581–589.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit